daratumumab
janssen
['mmsm', 'ifm2018-04']
congress | #eha2022 | cyrille touzeau presents results of phase ii ifm2018-04 trial inv. dara-krd induction in high-risk #myeloma.
- orr: 96%
- mrd neg: 62%
- well tolerated with no new safety signals and low grade of grade 3-4 traes
- longer follow-up is needed #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma